MAPKAPK2, a potential dynamic network biomarker of alpha-synuclein prior to its aggregation in PD patients

One of the important pathological features of Parkinson's disease (PD) is the pathological aggregation of alpha-synuclein (alpha-Syn) in the substantia nigra. Preventing the aggregation of alpha-Syn has become a potential strategy for treating PD. However, the molecular mechanism of alpha-Syn aggregation is unclear. In this study, using the dynamic network biomarker (DNB) method, we first identified the critical time point when alpha-Syn undergoes pathological aggregation based on a SH-SY5Y cell model and found that DNB genes encode transcription factors that regulated target genes that were differentially expressed. Interestingly, we found that these DNB genes and their neighbouring genes were significantly enriched in the cellular senescence pathway and thus proposed that the DNB genes HSF1 and MAPKAPK2 regulate the expression of the neighbouring gene SERPINE1. Notably, in Gene Expression Omnibus (GEO) data obtained from substantia nigra, prefrontal cortex and peripheral blood samples, the expression level of MAPKAPK2 was significantly higher in PD patients than in healthy people, suggesting that MAPKAPK2 has potential as an early diagnostic biomarker of diseases related to pathological aggregation of alpha-Syn, such as PD. These findings provide new insights into the mechanisms underlying the pathological aggregation of alpha-Syn.